Biogen Stock Forecast, Price & News

29 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 13 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biogen stock.
View analyst ratings for Biogen or view top-rated stocks.

Wall Street analysts have given Biogen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Biogen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Biogen saw a increase in short interest in August. As of August 13th, there was short interest totaling 2,180,000 shares, an increase of 21.8% from the July 29th total of 1,790,000 shares. Based on an average daily volume of 1,970,000 shares, the days-to-cover ratio is currently 1.1 days. Approximately 1.5% of the company's stock are sold short.
View Biogen's Short Interest.

Biogen is scheduled to release its next quarterly earnings announcement on Wednesday, October 20th 2021.
View our earnings forecast for Biogen.

Biogen Inc. (NASDAQ:BIIB) released its quarterly earnings data on Wednesday, July, 21st. The biotechnology company reported $5.68 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $4.55 by $1.13. The biotechnology company had revenue of $2.78 billion for the quarter, compared to analysts' expectations of $2.61 billion. Biogen had a net margin of 16.40% and a trailing twelve-month return on equity of 34.74%. The business's quarterly revenue was down 24.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $10.26 earnings per share.
View Biogen's earnings history.

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BIIB shares have increased by 0.0% and is now trading at $294.31.
View which stocks have been most impacted by COVID-19.

Biogen declared that its board has initiated a stock buyback program on Monday, December 23rd 2019, which allows the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company's leadership believes its stock is undervalued.

Biogen issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share (EPS) guidance of $17.500-$19.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $18.590. The company issued revenue guidance of $10.65 billion-$10.85 billion, compared to the consensus revenue estimate of $10.63 billion.

29 brokers have issued twelve-month price objectives for Biogen's shares. Their forecasts range from $245.00 to $500.00. On average, they expect Biogen's stock price to reach $393.36 in the next twelve months. This suggests a possible upside of 33.7% from the stock's current price.
View analysts' price targets for Biogen or view top-rated stocks among Wall Street analysts.

186 employees have rated Biogen CEO Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among Biogen's employees.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Repligen (RGEN), Novavax (NVAX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of BIIB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), The Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and The Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (11.04%), BlackRock Inc. (8.86%), Vanguard Group Inc. (7.89%), State Street Corp (4.48%), Jefferies Group LLC (0.00%) and Clearbridge Investments LLC (2.39%). Company insiders that own Biogen stock include Alfred Sandrock, Brian S Posner, Michel Vounatsos and Stephen A Sherwin.
View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, FMR LLC, LSV Asset Management, AQR Capital Management LLC, Bank of New York Mellon Corp, and Clearbridge Investments LLC. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, and Brian S Posner.
View insider buying and selling activity for Biogen or view top insider-selling stocks.

BIIB stock was acquired by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Amundi, Marshall Wace LLP, Squarepoint Ops LLC, American Century Companies Inc., Westfield Capital Management Co. LP, Legal & General Group Plc, and IMC Chicago LLC.
View insider buying and selling activity for Biogen or or view top insider-buying stocks.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIIB stock can currently be purchased for approximately $294.31.

Biogen has a market capitalization of $43.86 billion and generates $13.44 billion in revenue each year. The biotechnology company earns $4.00 billion in net income (profit) each year or $33.70 on an earnings per share basis.

Biogen employs 9,100 workers across the globe.

The following companies are subsidiares of Biogen: AliveGen, Biogen (Argentina) SRL, Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (Denmark) Manufacturing ApS, Biogen (Denmark) New Manufacturing ApS, Biogen (RTP) Realty LLC, Biogen (Singapore) Pte Ltd, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd., Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Colombia S.A.S., Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding APS, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Hong Kong Limited, Biogen Idec Ltd., Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia SRL, Biogen Japan Ltd., Biogen Korea, Biogen Luxembourg Holding SARL, Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen Mexico Servicios S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o, Biogen Poland Sp. z.o.o, Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Ltd., Eidetica Biopharma GmbH, Fumapharm, Karyopharm Therapeutics, Nightstar Europa Limited, Nightstar Inc., Nightstar Limited, Nightstar Therapeutics, Nightstar Therapeutics Limited, Old Convergence Pharmaceuticals Ltd., Panion Ltd., Remedy Pharmaceuticals, Silver Acquisition Co. Ltd., Stromedix, Stromedix Inc., Syntonix Pharmaceuticals, Tungsten Bidco Limited, and Tysabri.

Biogen was founded in 1978.

The official website for Biogen is www.biogen.com.

Biogen is headquartered at 225 BINNEY STREET, CAMBRIDGE MA, 02142.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (617) 679-2000 or via email at [email protected].